Brian M DeFeo1, Sue C Kaste2, Zhenghong Li3, Tara M Brinkman4, Michael D Neel5, Deo Kumar Srivastava6, Melissa M Hudson7, Leslie L Robison8, Seth E Karol9, Kirsten K Ness10. 1. DPT, OCS, Rehabilitation Services and Department of Radiological Sciences, Mail Stop 113, St Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis,TN 38105-3678 (USA). 2. Department of Radiological Sciences, St Jude Children's Research Hospital. 3. Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital. 4. Department of Epidemiology and Cancer Control and Department of Psychology, St Jude Children's Research Hospital. 5. Department of Surgery, St Jude Children's Research Hospital. 6. Department of Biostatistics and Department of Cancer Prevention and Control, St Jude Children's Research Hospital. 7. Department of Epidemiology and Cancer Control, Department of Psychology, Department of Cancer Prevention and Control, and Department of Oncology, St Jude Children's Research Hospital. 8. Department of Epidemiology and Cancer Control, Department of Cancer Prevention and Control, and Comprehensive Cancer Center, St Jude Children's Research Hospital. 9. Department of Oncology and Comprehensive Cancer Center, St Jude Children's Research Hospital. 10. Department of Epidemiology and Cancer Control and Department of Pediatric Medicine, St Jude Children's Research Hospital.
Abstract
BACKGROUND: Glucocorticoids used to treat childhood leukemia and lymphoma can result in osteonecrosis, leading to physical dysfunction and pain. Improving survival rates warrants research into long-term outcomes among this population. OBJECTIVE: The objective of this study was to compare the physical function and quality of life (QOL) of survivors of childhood cancer who had an osteonecrosis history with that of survivors who had no osteonecrosis history and with that of people who were healthy (controls). DESIGN: This was a cross-sectional study. METHODS: This study included St Jude Lifetime Cohort Study participants who were ≥ 10 years from the diagnosis of childhood leukemia or lymphoma and ≥ 18 years old; 135 had osteonecrosis (52.5% men; mean age = 27.7 [SD = 6.08] years) and 1560 had no osteonecrosis history (52.4% men; mean age = 33.3 [SD = 8.54] years). This study also included 272 people who were from the community and who were healthy (community controls) (47.7% men; mean age = 35.1 [SD = 10.46] years). The participants completed functional assessments and questionnaires about QOL. RESULTS: Survivors with osteonecrosis scored lower than other survivors and controls for dorsiflexion strength (mean score = 16.50 [SD = 7.91] vs 24.17 [SD = 8.61] N·m/kg) and scored lower than controls for flexibility with the sit-and-reach test (20.61 [SD = 9.70] vs 23.96 [SD = 10.73] cm), function on the Physical Performance Test (mean score = 22.73 [SD = 2.05] vs 23.58 [SD = 0.88]), and mobility on the Timed "Up & Go" Test (5.66 [SD = 2.25] vs 5.12 [SD = 1.28] seconds). Survivors with hip osteonecrosis requiring surgery scored lower than survivors without osteonecrosis for dorsiflexion strength (13.75 [SD = 8.82] vs 18.48 [SD = 9.04] N·m/kg), flexibility (15.79 [SD = 8.93] vs 20.37 [SD = 10.14] cm), and endurance on the 6-minute walk test (523.50 [SD = 103.00] vs 572.10 [SD = 102.40] m). LIMITATIONS: Because some eligible survivors declined to participate, possible selection bias was a limitation of this study. CONCLUSIONS: Survivors of childhood leukemia and lymphoma with and without osteonecrosis demonstrated impaired physical performance and reported reduced QOL compared with controls, with those requiring surgery for osteonecrosis most at risk for impairments. It may be beneficial to provide strengthening, flexibility, and endurance interventions for patients who have pediatric cancer and osteonecrosis for long-term function.
BACKGROUND: Glucocorticoids used to treat childhood leukemia and lymphoma can result in osteonecrosis, leading to physical dysfunction and pain. Improving survival rates warrants research into long-term outcomes among this population. OBJECTIVE: The objective of this study was to compare the physical function and quality of life (QOL) of survivors of childhood cancer who had an osteonecrosis history with that of survivors who had no osteonecrosis history and with that of people who were healthy (controls). DESIGN: This was a cross-sectional study. METHODS: This study included St Jude Lifetime Cohort Study participants who were ≥ 10 years from the diagnosis of childhood leukemia or lymphoma and ≥ 18 years old; 135 had osteonecrosis (52.5% men; mean age = 27.7 [SD = 6.08] years) and 1560 had no osteonecrosis history (52.4% men; mean age = 33.3 [SD = 8.54] years). This study also included 272 people who were from the community and who were healthy (community controls) (47.7% men; mean age = 35.1 [SD = 10.46] years). The participants completed functional assessments and questionnaires about QOL. RESULTS: Survivors with osteonecrosis scored lower than other survivors and controls for dorsiflexion strength (mean score = 16.50 [SD = 7.91] vs 24.17 [SD = 8.61] N·m/kg) and scored lower than controls for flexibility with the sit-and-reach test (20.61 [SD = 9.70] vs 23.96 [SD = 10.73] cm), function on the Physical Performance Test (mean score = 22.73 [SD = 2.05] vs 23.58 [SD = 0.88]), and mobility on the Timed "Up & Go" Test (5.66 [SD = 2.25] vs 5.12 [SD = 1.28] seconds). Survivors with hip osteonecrosis requiring surgery scored lower than survivors without osteonecrosis for dorsiflexion strength (13.75 [SD = 8.82] vs 18.48 [SD = 9.04] N·m/kg), flexibility (15.79 [SD = 8.93] vs 20.37 [SD = 10.14] cm), and endurance on the 6-minute walk test (523.50 [SD = 103.00] vs 572.10 [SD = 102.40] m). LIMITATIONS: Because some eligible survivors declined to participate, possible selection bias was a limitation of this study. CONCLUSIONS: Survivors of childhood leukemia and lymphoma with and without osteonecrosis demonstrated impaired physical performance and reported reduced QOL compared with controls, with those requiring surgery for osteonecrosis most at risk for impairments. It may be beneficial to provide strengthening, flexibility, and endurance interventions for patients who have pediatric cancer and osteonecrosis for long-term function.
Authors: C Liu; J D Kawedia; C Cheng; D Pei; C A Fernandez; X Cai; K R Crews; S C Kaste; J C Panetta; W P Bowman; S Jeha; J T Sandlund; W E Evans; C-H Pui; M V Relling Journal: Leukemia Date: 2012-04-09 Impact factor: 11.528
Authors: Gail D Deyle; Stephen C Allison; Robert L Matekel; Michael G Ryder; John M Stang; David D Gohdes; Jeremy P Hutton; Nancy E Henderson; Matthew B Garber Journal: Phys Ther Date: 2005-12
Authors: Kirsten K Ness; James G Gurney; Lonnie K Zeltzer; Wendy Leisenring; Daniel A Mulrooney; Paul C Nathan; Leslie L Robison; Ann C Mertens Journal: Arch Phys Med Rehabil Date: 2008-01 Impact factor: 4.060
Authors: Tosan Okoro; Rhiannon Whitaker; Andrew Gardner; Peter Maddison; John G Andrew; Andrew Lemmey Journal: BMC Musculoskelet Disord Date: 2016-04-21 Impact factor: 2.362
Authors: Uvaraj Periasamy; Marianne Chilutti; Summer L Kaplan; Christopher P Hickey; Katie Hayes; Jeffrey W Pennington; Fran Balamuth; Julie C Fitzgerald; Scott L Weiss Journal: Pediatr Crit Care Med Date: 2022-03-01 Impact factor: 3.624
Authors: Regine Söntgerath; Julia Däggelmann; Sabine V Kesting; Corina S Rueegg; Torge-Christian Wittke; Simon Reich; Katharina G Eckert; Sandra Stoessel; Carolina Chamorro-Viña; Joachim Wiskemann; Peter Wright; Anna Senn-Malashonak; Vanessa Oschwald; Anne-Marie Till; Miriam Götte Journal: Pediatr Res Date: 2021-04-15 Impact factor: 3.953
Authors: Wenjian Yang; Meenakshi Devidas; Yiwei Liu; Colton Smith; Yunfeng Dai; Naomi Winick; Stephen P Hunger; Mignon L Loh; Elizabeth A Raetz; Eric C Larsen; William L Carroll; Stuart S Winter; Kimberly P Dunsmore; Leonard A Mattano; Mary V Relling; Seth E Karol Journal: Blood Date: 2021-03-18 Impact factor: 22.113
Authors: Laura J Janke; Jieun Kim; Monique A Payton; David A Jenkins; Xiangjun Cai; Emily R Finch; Yiwei Liu; Mary V Relling; Seth E Karol Journal: Pediatr Blood Cancer Date: 2021-06-14 Impact factor: 3.838